GEN Exclusives

More »

GEN News Highlights

More »
Feb 18, 2009

HUYA Joins Forces with the Beijing Institute of Materia Medica

  • HUYA Bioscience is partnering with the Beijing Institute of Materia Medica (BIMM) on preclinical safety and efficacy activities as well as clinical trial protocols. The agreement also provides HUYA with the right of first review and negotiation for the licensing and development of certain new compounds owned or controlled by BIMM. This right includes drugs for cardiology, endocrinology, oncology, immunology, hematology, neuroscience, and infectious diseases.

    BIMM comprises the Chinese Academy of Medical Sciences and Peking Union Medical College. It concentrates on discovering and developing treatments by isolating natural remedies. “For BIMM,” says Xiaoling Wang, M.D., Ph.D., BIMM director, “our partnership with HUYA signifies an opportunity to bring our expertise and our efforts in pharmaceutical development to the Western market.”

    HUYA CEO, Mireille Gingras, Ph.D., adds that, “HUYA is highly experienced and uniquely positioned in China to leverage the emerging biotech industry through strong collaborations. This is the culmination of years of relationship-building and exchange of knowledge between HUYA and BIMM.”

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?